Exagen Inc. Common Stock (XGN) Stock
Key stats
- Market cap
- $128.46M
- Price / Earnings ratio
- -6.7x
- EPS (TTM)
- -$0.81
- Volume
- Loading
- 52-week high
- $9.74
- 52-week low
- $2.59
Source: third-party data provider, as of November 13, 2026
Compare with XGN
Recent news

Exagen Q2 Earnings Call Highlights
Exagen Q2 Earnings Call Highlights
XGN

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
XGN

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
XGN

Exagen Q1 Earnings Call Highlights
Exagen Q1 Earnings Call Highlights
XGN
Technical indicators
- RSI 14
- 32.58
- MACD 12/26/9
- -0.50
- EMA 9 of MACD
- -0.16
- MACD histogram
- -0.34
- SMA 50
- $7.84
- Price below SMA 50
- EMA 50
- $7.45
- Price below EMA 50
- SMA 200
- $5.12
- Price below SMA 200
- EMA 200
- $6.01
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Exagen Q2 Earnings Call Highlights
Exagen Q2 Earnings Call Highlights
XGN

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
XGN

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
XGN

Exagen Q1 Earnings Call Highlights
Exagen Q1 Earnings Call Highlights
XGN

Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates
Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates
XGN

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates
XGN

Time to Play 5 Top-Ranked Stocks With Rising P/E?
Time to Play 5 Top-Ranked Stocks With Rising P/E?
XGN
About Exagen Inc. Common Stock
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. John Aballi | CEO, President & Director | 1985 |
| Dr. Tina S. Nova Ph.D. | Executive Chairman of the Board of Directors | 1954 |
| Mr. Jeffrey G. Black | CFO & Corporate Secretary | 1969 |
| Dr. Michael Mahler | Chief Scientific Officer | — |
| Ms. Tina Jacobsen CFA | Vice President of Investor Relations | — |
| Dr. Prashanti Reddy M.D. | Chief Medical Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 32.58
- MACD 12/26/9
- -0.50
- EMA 9 of MACD
- -0.16
- MACD histogram
- -0.34
- SMA 50
- $7.84
- Price below SMA 50
- EMA 50
- $7.45
- Price below EMA 50
- SMA 200
- $5.12
- Price below SMA 200
- EMA 200
- $6.01
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $9.00
- Average
- $9.67
- High
- $11.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +42.7 | -13.1 | -3.8 | +56.8 | +14.2 | +8.9 | -39.9 |



